Gliclazide Modified Release Better Second-Line Treatment Tha
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Gliclazide modified release (MR) is more effective in reducing blood sugar levels than sitagliptin in type 2 diabetes (T2D) patients already taking metformin, a recent study published in the journal Diabetes, Obesity and Metabolism has pointed out. Gliclazide MR is available in India as Gliclazide XR (Extended Release) tablets

This study aimed to compare the effectiveness and safety of gliclazide modified release (MR) to sitagliptin as type 2 diabetes mellitus (T2D) treatments in a real-world patient population.

This retrospective cohort study used records from the UK Clinical Practice Research Datalink. The cohort consisted of adult patients with T2D newly treated with either gliclazide MR or sitagliptin as second-line treatment added to metformin and with a glycated hemoglobin (HbA1c) level of greater than or equal to 7.0% (53 mmol/mol).

Patients were 1:1 matched using high-dimensional propensity score matching and followed to determine the time taken to reach an HbA1c less than 7.0%. Secondary outcomes included time to HbA1c less than or equal to 6.5% (48 mmol/mol), time to greater than or equal to 1% (11 mmol/mol) HbA1c reduction from baseline, treatment persistence and durability, and hypoglycaemic events.

-- Among the 1986 patients included, those on gliclazide MR more likely achieved an HbA1c less than 7.0%, HbA1c less than or equal to 6.5% or had an HbA1c reduction greater than or equal to 1% from baseline compared with patients on sitagliptin.

-- Durability and persistence were similar between the two groups.

-- Hypoglycemic events were uncommon (23 total severe and non-severe events; incidence rate, 3.7 per 1000 patient years), with 4.7 and 2.6 events per 1000 patient years with gliclazide MR and sitagliptin treatment, respectively.

Conclusively, In this real-world study, second-line gliclazide MR was more effective than sitagliptin in reducing HbA1c, with similar durability and persistence and low rates of hypoglycemic events, in individuals with T2D on metformin treatment and HbA1c above the target of 7.0%.